Download

Full Text

• Mlost J. Bryk M. Starowicz K. Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action Int. J. Mol. Sci. 2020 21 8870 10.3390/ijms21228870 33238607
• Britch S.C. Babalonis S. Walsh S.H. Cannabidiol: Pharmacology and Therapeutic Targets Psychopharmacology 2021 238 9 28 10.1007/s00213-020-05712-8 33221931
• Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation Bioorganic Med. Chem. 2015 23 1377 1385 10.1016/j.bmc.2015.01.059 25703248
• Kirkland A.E. Fadus M.C. Gruber S.A. Gray K.M. Wilens T.E. Squeglia L.M. A scoping review of the use of cannabidiol in psychiatric disorders Psychiatry Res. 2022 308 114347 10.1016/j.psychres.2021.114347 34952255
• Franco V. Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy Drugs 2019 79 1435 1454 10.1007/s40265-019-01171-4 31372958
• Millar S.A. Stone N.L. Bellman Z.D. Yates A.S. England T.J. O’Sullivan S.E. A systematic review of cannabidiol dosing in clinical populations Br. J. Clin. Pharmacol. 2019 85 1888 1900 10.1111/bcp.14038 31222854
• Millar S.A. Stone N.L. Yates A.S. O’Sullivan S.E. A systematic review on the pharmacokinetics of cannabidiol in humans Front. Pharmacol. 2018 9 1365 10.3389/fphar.2018.01365
• Wakshlag J.J. Schwark W.S. Deabold K.A. Talsma B.N. Cital S. Lyubimov A. Iqbal A. Zakharov A. Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract Front. Vet. Sci. 2020 7 505 10.3389/fvets.2020.00505
• Deiana S. Watanabe A. Yamasaki Y. Amada N. Arthur M. Fleming S. Woodcock H. Dorward P. Pigliacampo B. Close S. et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour Psychopharmacology 2012 219 859 873 10.1007/s00213-011-2415-0
• Williams M.R. Holbrook T.C. Maxwell L. Croft C.H. Ientile M.M. Cliburn K. Pharmacokinetic Evaluation of a Cannabidiol Supplement in Horses J. Equine Vet. Sci. 2022 110 103842 10.1016/j.jevs.2021.103842
• Xu C. Chang T. Du Y. Yu C. Tan X. Li X. Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model Environ. Toxicol. Pharmacol. 2019 70 103202 10.1016/j.etap.2019.103202 31173966
• Turner S.E. Knych H.K. Adams A.A. Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses Am. J. Vet. Res. 2022 83 1 7 10.2460/ajvr.22.02.0028 35895770
• Hložek T. Uttl L. Kadeřábek L. Balíková M. Lhotková E. Horsley R.R. Nováková P. Šíchová K. Štefková K. Tylš F. et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC Eur. Neuropsychopharmacol. 2017 27 1223 1237 10.1016/j.euroneuro.2017.10.037 29129557
• Izgelov D. Davidson E. Barasch D. Regev A. Domb A.J. Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers Eur. J. Pharm. Biopharm. 2020 154 108 115 10.1016/j.ejpb.2020.06.021 32634571
• Jennotte O. Koch N. Lechanteur A. Evrard B. Development of amorphous solid dispersions of cannabidiol: Influence of the carrier, the hot-melt extrusion parameters and the use of a crystallization inhibitor J. Drug Deliv. Sci. Technol. 2022 71 103372 10.1016/j.jddst.2022.103372
• Koch N. Jennotte O. Gasparrini Y. Vandenbroucke F. Lechanteur A. Evrard B. Cannabidiol aqueous solubility enhancement: Comparison of three amorphous formulations strategies using different type of polymers Int. J. Pharm. 2020 589 119812 10.1016/j.ijpharm.2020.119812
• Cherniakov I. Izgelov D. Barasch D. Davidson E. Domb A.J. Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration J. Control. Release 2017 266 1 7 10.1016/j.jconrel.2017.09.011
• De Prá M.A.A. Vardanega R. Loss C.G. Lipid-based formulations to increase cannabidiol bioavailability: In vitro digestion tests, pre-clinical assessment and clinical trial Int. J. Pharm. 2021 609 121159 10.1016/j.ijpharm.2021.121159
• Jennotte O. Koch N. Lechanteur A. Rosoux F. Emmerechts C. Beeckman E. Evrard B. Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule Int. J. Pharm. 2023 646 123506 10.1016/j.ijpharm.2023.123506
• Koch N. Jennotte O. Toussaint C. Lechanteur A. Evrard B. Production challenges of tablets containing lipid excipients: Case study using cannabidiol as drug model Int. J. Pharm. 2023 633 122639 10.1016/j.ijpharm.2023.122639
• Lee S.Y. Lee D.Y. Kang J.H. Jeong J.W. Kim J.H. Kim H.W. Oh D.H. Kim J.M. Rhim S.J. Kim G.D. et al. Alternative experimental approaches to reduce animal use in biomedical studies J. Drug Deliv. Sci. Technol. 2022 68 103131 10.1016/j.jddst.2022.103131
• Pestieau A. Lebrun S. Cahay B. Brouwers A. Streel B. Cardot J.M. Evrard B. Evaluation of different in vitro dissolution tests based on level A in vitro–in vivo correlations for fenofibrate self-emulsifying lipid-based formulations Eur. J. Pharm. Biopharm. 2017 112 18 29 10.1016/j.ejpb.2016.10.030 27865930
• Devinsky O. Kraft K. Rusch L. Fein M. Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study J. Pharm. Sci. 2021 110 3946 3952 10.1016/j.xphs.2021.08.012 34400185
• Lucas C.J. Galettis P. Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids Br. J. Clin. Pharmacol. 2018 84 2477 2482 10.1111/bcp.13710 30001569
• Kevin R.C. Vogel R. Doohan P. Berger M. Amminger G.P. McGregor I.S. A validated method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial Drug Test. Anal. 2021 13 614 627 10.1002/dta.2947 33095968
• Malaca S. Gottardi M. Pigliasco F. Barco S. Cafaro A. Amadori E. Riva A. Marcenaro M. Striano P. Cangemi G. et al. UHPLC-MS/MS analysis of cannabidiol and its metabolites in serum of patients with resistant epilepsy treated with CBD formulations Pharmaceuticals 2021 14 630 10.3390/ph14070630 34209666
• Lo Faro A.F. Tini A. Gottardi J. Pichini S. Carlier J. Giorgetti R. Busardò F.P. UHPLC-MS-MS Determination of THC, CBD and Their Metabolites in Whole Blood of Light Cannabis Smokers J. Anal. Toxicol. 2023 46 e256 e261 10.1093/jat/bkac081
• Nicolaou A.G. Christodoulou M.C. Stavrou I.J. Kapnissi-Christodoulou C.P. Analysis of cannabinoids in conventional and alternative biological matrices by liquid chromatography: Applications and challenges J. Chromatogr. A 2021 1651 462277 10.1016/j.chroma.2021.462277
• González O. Alonso R.M. Validation of bioanalytical chromatographic methods for the quantification of drugs in biological fluids Handb. Anal. Sep. 2020 7 115 134 10.1016/B978-0-444-64066-6.00006-X
• Tiwari G. Tiwari R. Bioanalytical method validation: An updated review Pharm. Methods 2010 1 25 38 10.4103/2229-4708.72226
• Moein M.M. El Beqqali A. Abdel-Rehim M. Bioanalytical method development and validation: Critical concepts and strategies J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2017 1043 3 11 10.1016/j.jchromb.2016.09.028 27720355
• Hahirwa I. Charlier C. Karangwa C. Denooz R. Validation of an analytical method for the determination in serum of psychotropic drugs by High-Performance Liquid Chromatography with Diode Array Detection Rwanda J. 2015 2 13 23 10.4314/rjhs.v2i1.2F
• Pirard C. Charlier C. Simple and fast method for the measurement of legacy and novel brominated flame retardants in human serum Chemosphere 2018 211 918 925 10.1016/j.chemosphere.2018.08.012 30119023
• Pichini S. Mannocchi G. Gottardi M. Pérez-Acevedo A.P. Poyatos L. Papaseit E. Pérez-Mañá C. Farré M. Pacifici R. Busardò F.P. Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual Talanta 2020 209 120537 10.1016/j.talanta.2019.120537 31892011
• Sánchez de Medina A. Serrano-Rodríguez J.M. Díez de Castro E. García-Valverde M.T. Saitua A. Becero M. Muñoz A. Ferreiro-Vera C. Sánchez de Medina V. Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations Equine Vet. J. 2023 55 1094 1103 10.1111/evj.13923 36624043
• Meyer P. Langos M. Brenneisen R. Human Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations Med. Cannabis Cannabinoids 2018 1 36 43 10.1159/000489034 34676320
• Cherniakov I. Izgelov D. Domb A.J. Hoffman A. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model Eur. J. Pharm. Sci. 2017 109 21 30 10.1016/j.ejps.2017.07.003
• Ferreira L. Campos J. Veiga F. Cardoso C. Paiva-Santos A.C. Cyclodextrin-based delivery systems in parenteral formulations: A critical update review Eur. J. Pharm. Biopharm. 2022 178 35 52 10.1016/j.ejpb.2022.07.007
• Jones D.S. Dressman J.B. Loftsson T. Moya-Ortega M.D. Alvarez-Lorenzo C. Concheiro A. Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug/cyclodextrin complexes J. Pharm. Pharmacol. 2016 68 544 555 10.1111/jphp.12427
• Hatziagapiou K. Bethanis K. Koniari E. Christoforides E. Nikola O. Andreou A. Mantzou A. Chrousos G.P. Kanaka-Gantenbein C. Lambrou G.I. Biophysical Studies and In Vitro Effects of Tumor Cell Lines of Cannabidiol and Its Cyclodextrin Inclusion Complexes Pharmaceutics 2022 14 706 10.3390/pharmaceutics14040706
• Piel G. Evrard B. Van Hees T. Delattre L. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution Int. J. Pharm. 1999 180 41 45 10.1016/S0378-5173(98)00403-7 10089290
• Salles É.L. Khodadadi H. Jarrahi A. Ahluwalia M. Paffaro V.A. Costigliola V. Yu J.C. Hess D.C. Dhandapani K.M. Baban B. Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome J. Cell. Mol. Med. 2020 24 12869 12872 10.1111/jcmm.15883 33058425
• Wolfgang A.R. Greogory L.K. Handbook of Basic Pharmacokinetics: Including Clinical Applictions American Pharmacists Association Washington, DC, USA 2009
• Linderkamp O. Betke K. Güntner M. Jap G.H. Riegel K.P. Walser K. Blood volume in newborn piglets: Effects of time of natural cord rupture, intra-uterine growth retardation, asphyxia, and prostaglandin-induced prematurity Pediatr. Res. 1981 15 53 57 10.1203/00006450-198101000-00013 6894190